Steve, who joined Ampersand as an Executive Advisor in 2022, is a passionate life sciences investor and entrepreneur. He is currently President and CEO of Ampersand portfolio company Genezen, a leading viral vector CDMO. Prior, Steve was CFO at Arbor Biotechnologies, a next generation gene editing therapeutic company. Steve also served as CFO at Ampersand portfolio company Arranta Bio, a leading CDMO for mRNA, from its founding in 2019 to its sale to Recipharm in February 2022. Prior to this, Steve was CFO at Ampersand portfolio company Brammer Bio, where he oversaw a period of rapid expansion and capital deployment from 2016 to 2019, growing the company from 80 employees to over 650 at the time of its sale to Thermo Fisher Scientific in May 2019. Prior to joining Brammer, Steve had finance roles of increasing responsibility at Millipore, Merck KGaA, and Bruker Corporation. He received his M.B.A. and M.S. from the Carroll School of Management at Boston College and a B.A. in Economics from Boston College.